David C Taussig
Overview
Explore the profile of David C Taussig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1008
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhatla T, Hogan L, Teachey D, Bautista F, Moppett J, Velasco Puyo P, et al.
Blood
. 2024 Aug;
144(21):2237-2247.
PMID: 39158071
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg...
2.
Sekeres M, Montesinos P, Novak J, Wang J, Jeyakumar D, Tomlinson B, et al.
Leukemia
. 2023 Aug;
37(10):2017-2026.
PMID: 37604981
This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine)...
3.
Casado P, Rio-Machin A, Miettinen J, Bewicke-Copley F, Rouault-Pierre K, Krizsan S, et al.
Signal Transduct Target Ther
. 2023 Feb;
8(1):80.
PMID: 36843114
Acute myeloid leukaemia (AML) patients harbouring certain chromosome abnormalities have particularly adverse prognosis. For these patients, targeted therapies have not yet made a significant clinical impact. To understand the molecular...
4.
de Botton S, Fenaux P, Yee K, Recher C, Wei A, Montesinos P, et al.
Blood Adv
. 2023 Feb;
7(13):3117-3127.
PMID: 36724515
Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH1 inhibitor-naive patients with mIDH1R132 relapsed/refractory (R/R) acute myeloid leukemia (AML) received olutasidenib...
5.
Iland H, Russell N, Dillon R, Schuh A, Tedjaseputra A, Wei A, et al.
Blood Adv
. 2022 Sep;
7(11):2580-2585.
PMID: 36075018
No abstract available.
6.
Zeidan A, Boss I, Beach C, Copeland W, Thompson E, Fox B, et al.
Blood Adv
. 2021 Dec;
6(7):2219-2229.
PMID: 34933333
Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death-ligand 1 (PD-L1) inhibitor, combined...
7.
Tiong I, Dillon R, Ivey A, Teh T, Nguyen P, Cummings N, et al.
Br J Haematol
. 2020 May;
192(6):1026-1030.
PMID: 32458446
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or...
8.
Moore A, Faisal A, Mak G, Miraki-Moud F, Bavetsias V, Valenti M, et al.
Blood Adv
. 2020 Apr;
4(7):1478-1491.
PMID: 32282883
Internal tandem duplication of FLT3 (FLT3-ITD) is one of the most common somatic mutations in acute myeloid leukemia (AML); it causes constitutive activation of FLT3 kinase and is associated with...
9.
Ghazaly E, Miraki-Moud F, Smith P, Gnanaranjan C, Koniali L, Oke A, et al.
J Biol Chem
. 2020 Mar;
295(16):5496-5508.
PMID: 32161116
Previous studies have shown that sphingosine kinase interacting protein (SKIP) inhibits sphingosine kinase (SK) function in fibroblasts. SK phosphorylates sphingosine producing the potent signaling molecule sphingosine-1-phosphate (S1P). gene () expression...
10.
Griessinger E, Vargaftig J, Horswell S, Taussig D, Gribben J, Bonnet D
Exp Hematol
. 2017 Dec;
59:66-71.e4.
PMID: 29253573
Xenograft assay allows functional analysis of leukemia-initiating cells of acute myeloid leukemia primary samples. However, 40% of samples derived from patients with better outcomes fail to engraft in immunodeficient mouse...